Literature DB >> 12837628

Nogo-C is sufficient to delay nerve regeneration.

Ji Eun Kim1, Iris E Bonilla, Dike Qiu, Stephen M Strittmatter.   

Abstract

Axonal regeneration succeeds in the peripheral but not central nervous system of adult mammals. Peripheral clearance of myelin coupled with selective CNS expression of axon growth inhibitors, such as Nogo, may account for this reparative disparity. To assess the sufficiency of Nogo for limiting axonal regeneration, we generated transgenic mice expressing Nogo-C in peripheral Schwann cells. Nogo-C includes the panisoform inhibitory Nogo-66 domain, but not a second Nogo-A-specific inhibitory domain, allowing a selective consideration of the Nogo-66 region. The oct-6::nogo-c transgenic mice regenerate axons less rapidly than do wild-type mice after mid-thigh sciatic nerve crush. The delayed axonal regeneration is associated with a decreased recovery rate for motor function after sciatic nerve injury. Thus, expression of the Nogo-66 domain by otherwise permissive myelinating cells is sufficient to hinder axonal reextension after trauma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12837628     DOI: 10.1016/s1044-7431(03)00076-9

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  15 in total

1.  Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo.

Authors:  Y Albert Pan; Thomas Misgeld; Jeff W Lichtman; Joshua R Sanes
Journal:  J Neurosci       Date:  2003-12-10       Impact factor: 6.167

2.  Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins.

Authors:  William A Barton; Betty P Liu; Dorothea Tzvetkova; Philip D Jeffrey; Alyson E Fournier; Dinah Sah; Richard Cate; Stephen M Strittmatter; Dimitar B Nikolov
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

Review 3.  Extracellular regulators of axonal growth in the adult central nervous system.

Authors:  Betty P Liu; William B J Cafferty; Stephane O Budel; Stephen M Strittmatter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-09-29       Impact factor: 6.237

4.  Protein folding at the membrane interface, the structure of Nogo-66 requires interactions with a phosphocholine surface.

Authors:  Sheeja V Vasudevan; Jessica Schulz; Chunyi Zhou; Melanie J Cocco
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

5.  Nogo-B receptor modulates angiogenesis response of pulmonary artery endothelial cells through eNOS coupling.

Authors:  Ru-Jeng Teng; Ujala Rana; Adeleye J Afolayan; Baofeng Zhao; Qing R Miao; Girija G Konduri
Journal:  Am J Respir Cell Mol Biol       Date:  2014-08       Impact factor: 6.914

6.  Transgenic inhibition of Nogo-66 receptor function allows axonal sprouting and improved locomotion after spinal injury.

Authors:  Shuxin Li; Ji-Eun Kim; Stephane Budel; Thomas G Hampton; Stephen M Strittmatter
Journal:  Mol Cell Neurosci       Date:  2005-05       Impact factor: 4.314

Review 7.  Myelin associated inhibitors: a link between injury-induced and experience-dependent plasticity.

Authors:  Feras Akbik; William B J Cafferty; Stephen M Strittmatter
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

8.  Nogo-C contributes to HCC tumorigenesis via suppressing cell growth and its interactome analysis with comparative proteomics research.

Authors:  Xing Liu; Shu-Jian Cui; Shi-Jun Zhu; De-Chun Geng; Long Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 9.  Axon regeneration in the peripheral and central nervous systems.

Authors:  Eric A Huebner; Stephen M Strittmatter
Journal:  Results Probl Cell Differ       Date:  2009

10.  Recombinant DNA vaccine against inhibition of neurite outgrowth promotes functional recovery associated with endogeous NGF expression in spinal cord hemisected adult rats.

Authors:  Yi Zhang; Chun-Guang Hao; Li-Qun Hu; Jian Dong; Peng Wei; Dan Xu; Zhi-Cheng Xiao; Ting-Hua Wang
Journal:  Neurochem Res       Date:  2009-04-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.